Escolar Documentos
Profissional Documentos
Cultura Documentos
Equlíbrio da microbiota intestinal Human clinical: trial Del Piano M. et al. The use of probiotics in the treatment of
Bifidobacteruim constipation in the elderly. CIBUS, 2005; 1(1):23-30. In vitro study: Rossi M. et al.
Fermentation of fructooligosaccharides and inulin by Bifidobacteria: a comparative study
adolescentis BA02 Trânsito intestinal
of pure and fecal cultures. Applied and Environmental Microbiology, 2005; 71(10): 6150-
10 bilhões de UFC
prebiótica
Produção de ácido fólico Human pilot clinical trial: Strozzi GP. and Mogna L. Quantification of folic acid in
human faeces after administration of Bifidobacterium probiotic strains. Journal of Clinical
Bifidobacterium Gastroenterology, 2008; 42:S179-S184. Animal model study Pompei A. et al.
animalis subsp. lactis Administration of Folate-Producing Bifidobacteria Enhances Folate Status in Wistar Rats. 5 bilhões UFC
Journal of Nutrition, 2007; 137:2742-2746. In vitro study: Pompei A. et al. Folate
BA05 (DSM 18352) production by Bifidobacteria as a potential probiotic property. Applied and Environmental
Equlíbrio da microbiota intestinal Microbiology, 2007; 73(1):179-185
Human pilot clinical trial: Strozzi GP. and Mogna L. Quantification of folic acid in
Bifidobacterium Produção de ácido fólico human faeces after administration of Bifidobacterium probiotic strains. Journal of Clinical
catenulatum/ Gastroenterology, 2008; 42:S179-S184. Animal model study: Pompei A. et al.
Administration of Folate-Producing Bifidobacteria Enhances Folate Status in Wistar Rats. 5 bilhões UFC
pseudocatenulatum Journal of Nutrition, 2007; 137:2742-2746. In vitro study: Pompei A. et al. Folate
BA03 (DSM 18350) Equlíbrio da microbiota intestinal production by Bifidobacteria as a potential probiotic property. Applied and Environmental
Microbiology, 2007; 73(1):179-185
Cepas de Bifidobactérias
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Efeito imunomodulador
relacionado a asma
Produção de ácido fólico Human pilot clinical trial: Strozzi GP. and Mogna L. Quantification of folic acid in
Bifidobacterium human faeces after administration of Bifidobacterium probiotic strains. Journal of Clinical
catenulatum/ Gastroenterology, 2008; 42:S179-S184. Animal model study: Pompei A. et al.
Administration of Folate-Producing Bifidobacteria Enhances Folate Status in Wistar Rats. 5 bilhões UFC
pseudocatenulatum Journal of Nutrition, 2007; 137:2742-2746. In vitro study: Pompei A. et al. Folate
production by Bifidobacteria as a potential probiotic property. Applied and Environmental
BC01 (DSM 18353) Equilíbrio da microbiota intestinal Microbiology, 2007; 73(1):179-185
Cepas de Bifidobactérias
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Inibição de Klebsiella
pneumoniae e de outros
coliformes isolados de crianças
com cólera
In vitro studies: 1) Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the
treatment of enteric disorders in newborns. Appl Microbiol Biotechnol. 2012; 96(6):1561-
Bifidobacterium
Equilíbrio da microbiota intestinal 76. 2) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic
breve bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46
Suppl:S29-32. 3) Simone M. et al. The probiotic Bifidobacterium breve B632 Inhibited the
B632 (DSM 24706) Growth of Enterobacteriaceae within Colicky Infant Microbiota Cultures. Biomed Res Int.
Redução do desconforto 2014; 2014:301053.
gastrointestinal
Inibição de E. coli
Bifidobacterium
bifidum Equilíbrio da microbiota intestinal
BB01 (DSM 19818)
Cepas de Bifidobactérias
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Bifidobacterium
lactis Saúde cardiovascular
Redução do desconforto
Human clinical trials: 1) Amenta M. et al. Diet and chronic constipation. Benefits of oral
gastrointestinal relacionado a supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight).
síndrome do intestino irritável Acta Biomed 2006; 77(3):157-62. 2) Colecchia A. et al. Symbiotic Study Group. Effect of
a symbiotic preparation on the clinical manifestations of irritable bowel syndrome,
constipation-variant. Results of an open, uncontrolled multicenter study. Minerva
Gastroenterol Dietol 2006; 52(4):349-58. 3) Fanigliulo L. et al. Role of gut microflora and
probiotic effects in the irritable bowel syndrome. Acta Biomed 2006; 77(2):85-9. 4)
Bifidobacterium Sarnelli G. et al. Effects of oral supplementation with the symbiotic (Bifidobacterium
1,2,3,4,5,6)
5 bilhões CFU
longum Equilíbrio da microbiota longum W11 + FOS Actilight) on IBS with constipation: a randomized, dose finding trial,
+
versus fibers. Digestive and Liver Disease 2008; 40(1):S141. 5) Malaguarnera M. et al.
W11 Bifidobacterium longum with fructo-oligosaccharides (FOS) treatment in minimal hepatic
FOS
encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;
52:3259-3265. 6)Dughera L. et al. Effects of symbiotic preparation on constipated irritable
bowel syndrome symptoms. Acta Biomed 2007; 78:111-116. In vitro study: Graziano T.
et al. The possible innovative use of Bifidobacterium longum W11 in association with
Resistência à rifamicinas não rifaximin: a new horizon for combined approach? Publication in progress in a Supplement
transmissíveis to the Journal of Clinical Gastroenterology.
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Melhor imunidade
Lactobacillus
fermentum ME-3 Saúde cardiovascular Existem muitos estudos clínicos em humanos
(Sob licença da Universidade de
Tartu para aplicações alimentícias)
Antioxidante
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
Animal model study: Zarate G. et al. Protective Effect of Vaginal Lactobacillus
paracasei Saúde vaginal paracasei CRL 1289 against Urogenital Infection Produced by Staphylococcus aureus in
subsp. paracasei a Mouse Animal Model. Infect Dis Obstet Gynecol. 2009;2009:48358. In vitro studies: 1)
Ocana VS. et al. Selection of vaginal H2O2- generating Lactobacillus species for probiotic
CRL 1289 use. Current Microbiology, 1999; 38: 279-84; 2) Zàrate G. and Nader-Macias ME.
Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to
(under worldwide vaginal epithelial cells. Letters in Applied Microbiology ISSN 0266-8254; 3) Ocana VS. et
exclusive Inibição de al. Growth inhibition of Staphylococcus aureus by H2O2-producing Lactobacillus
Staphyloccocus paracasei subsp. paracasei isolated from the human vagina. FEMS Immunology and
license from the Medical Microbiology, 1999; 23:87-92.
Aureus
CERELA)
Lactobacillus In vitro studies: 1) Tomas MSJ. et al. Growth and lactic acid production by vaginal
gasseri Saúde vaginal Lactobacillus acidophilus CRL 1259, and inhibition of uropathogenic Escherichia coli.
Journal of Medical Microbiology, 2003; 52:1-8; 2) Ocana V. and Nader-Macias ME.
CRL 1259 Adhesion of Lactobacillus vaginal strains with probiotic properties to vaginal epithelial
(under worldwide cells. Biocell, 2001; 25(3): 265-273; 3) Tomas MSJ. et al. Characterization of potentially
probiotic vaginal lactobacilli isolated from Argentinean women. British Journal of
exclusive Biomedical Science, 2005; 62(4); 4) Zàrate G. and Nader-Macias ME. Influence of
license from the Produção de ácido lático probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal
epithelial cells. Letters in Applied Microbiology ISSN 0266-8254.
CERELA)
Lactobacillus Trânsito intestinal In vitro study: Mogna L. et al. Assessment of the in vitro inhibitory activity of specific
plantarum probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46
Suppl:S29-32.
LP02 (LMG P-21020) Inibição de E. coli
Lactobacillus
delbrueckii
Equilíbrio da microbiota
subsp. bulgaricus
LDB01 (DSM 16606)
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
1) 10 bilhões
Equilíbrio da microbiota
Lactobacillus Human clinical trials: 1) Dezi A. et al. Probiotics and chronic diarrhea in the elderly. CFU
CIBUS, 2004; 8(2):58-64. 2) Del Piano M. et al. Comparison of the kinetics of intestinal 2) 5 bilhões CFU
rhamnosus colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or (não revestido)
LR04 (DSM 16605) Trânsito intestinal
in a traditional, uncoated form. J Clin Gastroenterol. 2012; 46 Suppl:S85-92. 1 bilhão de células
(Microencapsulado)
Inibição de E. coli incluindo In vitro studies presented in 2009 and in 2010 (Probiotic Congress, Rome, Italy): 1)
toxinogênico O157:H7 Nicola S. et al. Interaction between probiotics and human immune system: two strains
Lactobacillus with reverse immunomodulatory activities. (IPA World Congress, Miami, USA) 2) Nicola
pentosus S. et al. Bifidobacterium breve BR03 and Lactobacillus pentosus LPS01 differentially
regulate cytokines release in human peripheral blood mononuclear cells. In vitro study
LPS01 (DSM 21980) Fortalecimento das defesas Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria
naturais do organismo against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
Lactobacillus
brevis Atividade Antioxidante
LBR01 (DSM 23034) In vitro and animal model studies: Amaretti A. et al. Antioxidant properties of
potentially probiotic bacteria: in vitro and in vivo activities. Appl Microbiol Biotechnol.
Lactobacillus 2013; 97(2):809-17. Human clinical trial: under publication.
Redução da glutationa (GSH) e
acidophilus produção de superóxido
LA06 (DSM 23033) dismutase (SOD)
Lactobacillus
plantarum Atividade contra Listeria
Monocytogenes
LP03 (LMG P-21022)
ATCC 19112 e In vitro study
Lactobacillus Escherichia coli
plantarum ATCC 35218
LP04 (LMG P-21023)
Equlíbrio da microbiota intestinal Human clinical trials: 1) Drago L. et al. Effects of Lactobacillus salivarius LS01 (DSM
22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J
Immunopathol Pharmacol. 2011; 24(4):1037-48. 2) Drago L. et al. Changing of fecal flora 1,2,3)
and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. J Clin 2 bilhões CFU
Lactobacillus Gastroenterol. 2012; 46 Suppl:S56-63. 3) Niccoli A. et al. Preliminary results on clinical 4) 5 bilhões CFU
Saúde da pele
effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis. +
salivarius J Clin Gastroenterol. 2014; 48 Suppl:S34-36. 4) Drago L. et al. Treatment of atopic 2 bilhões CFU de
dermatitis eczema with a high concentration of Lactobacillus salivarius LS01 associated Streptococcus
subsp. salivarius
Melhoria da qualidade de vida em with an innovative gelling complex. J Clin Gastroenterol. 2014; 48 Suppl:S47-51. In vitro thermophilus
LS01 (DSM 22775) casos de dermatite atópica studies: a) Drago L. et al. Strain-dependent release of cytokines modulated by ST10
Lactobacillus salivarius human isolates in an in vitro model. BMC Res Notes. 2010; 3:44. +
b) Drago L. et al. Immunomodulatory effects of Lactobacillus salivarius LS01 and Goma de Tara
Efeito imunomodulador Bifidobacterium breve BR03, alone and in combination, on peripheral blood mononuclear
relacionado a asma cells of allergic asthmatics. Allergy Asthma Immunol Res. 2015 July; 7(4):409-413
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
paracasei Degradação de oxalato
LPC09 (DSM 24243)
Lactobacillus
gasseri
LGS01 (DSM 18299) Redução de inflamação intestinal
Lactobacillus In vitro study: Mogna L. et al. Screening of different probiotic strains for their in vitro
gasseri ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol.
2014; 48 Suppl:S91-95
LGS02 (DSM 18300)
Potencial redução de incidência
Lactobacillus de pedras no rim
acidophilus
LA07 (DSM 24303)
Lactobacillus
Redução de desconforto
acidophilus gastrointestinal
LA02 (DSM 21717)
Lactobacillus
In vitro study: Nicola S. In vitro evaluation of the immunomodulating properties of the
rhamnosus Equlíbrio da microbiota intestinal
strain Lactobacillus rhamnosus LR05 (DSM 19739)
LR05 (DSM 19739)
Equlíbrio da microbiota intestinal Human clinical trial: Del Piano M. et al. Comparison of the kinetics of intestinal
Lactobacillus colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or 5 bilhões CFU
in a traditional, uncoated form. J Clin Gastroenterol. 2012; 46 Suppl:S85-92. In vitro (Não revestido)
rhamnosus study: Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic 1 bilhão de células
LR06 (DSM 21981) Inibição de E. coli incluindo bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 (Microencapsulado)
Suppl:S29-32.
toxinogênico O157:H7
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Saúde vaginal In vitro study: Deidda F. et al. In vitro effectiveness of Lactobacillus fermentum against
Lactobacillus different Candida species compared with broadly used azoles. Publication in progress in
a Supplement to the Journal of Clinical Gastroenterology. In vitro data: Vicariotto F. et
fermentum Inibição de cepas de candida 800 milhões CFU
al. Effectiveness of the association of 2 probiotic strains formulated in a slow release
LF11 (DSM 19188) Neutralização de candidíase
vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin
Gastroenterol. 2012; 46 Suppl:S73-80
vulvovaginal
Lactobacillus
fermentum Inibição de cepas de candida In vitro data
LF15 (DSM 26955) fermentum against different Candida species compared with broadly used azoles.
Neutralização de vaginose Publication in progress in a Supplement to the Journal of Clinical Gastroenterology.
bacteriana
Lactobacillus
rhamnosus
GG (ATCC 53103)
(Produtor autorizado VALIO)
Uma das cepas probióticas mais conhecidas do mundo.
5 bilhões UFC
Lactobacillus Many human clinical trials are available: Del Piano M. et al. Comparison of the
(não revestido)
kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a
rhamnosus microencapsulated or in a traditional, uncoated form. J Clin Gastroenterol. 2012; 46
1 bilhão de células
(microencapsulado)
GG (ATCC 53103) Suppl:S85-92.
Active
Pharmaceutical
Ingredient
(Sob licença de VALIO)
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Redução de desconforto
gastrointestinal
Equlíbrio da microbiota intestinal Human clinical trials: 1) Del Piano M. et al., The use of probiotics in the treatment of
constipation in the elderly. CIBUS, 2005; 1(1):23-30. 2) Del Piano M. et al. Evaluation of
the intestinal colonization by microencapsulated probiotic bacteria in comparison with the
Trânsito intestinal 1) 10 bilhões
same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6. 3) Del Piano M. et
Lactobacillus al. Is microencapsulation the future of probiotic preparations? The increased efficacy of
UFC
Inibição de E. Coli 2,3) 5 bilhões
plantarum gastro-protected probiotics. Gut Microbes. 2011; 2(2):120-3. In vitro study presented in
UFC (não revestido)
2009: (Probiotic Congress, Rome, Italy) Nicola S. et al. Interaction between probiotics
LP01 (LMG P-21021) Atividade contra Listeria and human immune system: two strains with reverse immunomodulatory activities. In
1 bilhão de células
(microencapsulado)
Monocytogenes vitro study: Mogna L. et al. Assessment of the in vitro inhibitory activity of specific
ATCC 19112, probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46
Enterococcus sp. Suppl:S29-32.
(fezes de recém-nascidos),
Klebsiella sp. (fezes de recém-
nascidos)
Inibição de Listeria
Lactobacillus Monocytogenes
Lactobacillus
casei Equlíbrio da microbiota intestinal
LC03 (DSM 27537)
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
reuteri LRE02 Produção de Riboflavina In vitro study
(DSM 23878)
Lactobacillus
reuteri LRE01
(DSM 23877)
Equlíbrio da microbiota intestinal
Lactobacillus
reuteri LRE04
(DSM 23880)
Cepas de Lactobacillus
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Produção de exopolissacarídeos
Streptococcus (EPS) no intestino
Human clinical trial: Del Piano M. et al. Assessment of the capability of a gelling
complex made of tara gum and the exopolysaccharides (EPS) produced by the
thermophilus ST10 microorganisms Streptococcus thermophilus ST10 (DSM 25246) to prospectively restore
1 bilhão UFC
(DSM 25246) Restauração da barreira the gut physiological barrier: a pilot study. J Clin Gastroenterol. 2014; 48 Suppl:S56-61.
fisiológica intestinal
Streptococcus
thermophilus YO8
(DSM 17843)
Streptococcus
Redução do gosto do grão no In vitro study: Patent Application WO/2009/106536. Fermented soymilk and method for
thermophilus YO5 leite de soja fermentado improving the organoleptic properties of fermented soymilk.
(DSM 16593)
Streptococcus
thermophilus YO3
(DSM 16591)
Streptococcus
Usado no leite de vaca para
thermophilus YO4 elaboração de iogurte
(DSM 16592)
Streptococcus
Potencial redução de incidência
thermophilus FP4 de alergias
(DSM 18616)
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
1) 5 bilhões UFC
Human clinical trials: 1) Saggioro A. Probiotics in the treatment of Irritable Bowel +
Bifidobacterium Trânsito intestinal Syndrome Journal of Clinical Gastroenterology, 2004; 38(8): S104-106. 2) Del Piano et al. 5 bilhões UFC
breve BR03 Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in 2,4) 5 bilhões UFC/
comparison to the same uncoated strains. Journal of Clinical Gastroenterology, 2010; cepas
(DSM 16604) 44(8):S42-46. 3) Del Piano et al. The use of probiotics in healthy volunteers with (não revestido)
Redução de desconforto
+ gastrointestinal
evacuation disorders and hard stools. A double blind, randomized, placebo-controlled vs.
study. Journal of Clinical Gastroenterology, 2010; 44(8):S30-34. 4) Del Piano M. et al. Is 1 bilhão
Lactobacillus microencapsulation the future of probiotic preparations? The increased efficacy of gastro- células/cepas
plantarum Inibição de E. coli incluindo
protected probiotics. Gut Microbes. 2011; 2(2):120-3. In vitro study: Mogna L. et al. (microencapsulado)
Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different 3) 2.5 bilhões UFC
LP01 (LMG P-21021) toxinogênico O157:H7 Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32. +
2.5 bilhões UFC
Restauração da barreira
fisiológica intestinal
Lactobacillus
Redução de desconforto
acidophilus gastrointestinal
LA02 (DSM 21717) Human clinical trial: Saggioro A. Probiotics in the treatment of Irritable Bowel
5 bilhões UFC
Syndrome. Journal of Clinical Gastroenterology, 2004; 38(8): S104-106. In vitro study:
+ Nicola S. et al. Immunomodulation properties of Lactobacillus plantarum LP01 (LMG P-
+
5 bilhões UFC
Lactobacillus 21021) and Lactobacillus acidophilus LA02 (DSM 21717) blend.
Lactobacillus
plantarum Redução da incidência,
gravidade e duração de infecção
LP02 (LMG P-21020) aguda respiratória (IAR) em
estações frias
Bifidobacterium
lactis
Saúde cardiovascular
MB2409 (DSM 23733)
+
Bifidobacterium Human clinical trial: Guardamagna O. et al. Bifidobacteria supplementation: effects on
1 bilhão UFC/
bifidum plasma lipid profile in dyslipidemic children. Nutrition (2014), doi:
cepas
10.1016/j.nut.2014.01.014.
MB109 (DSM 23731)
+
Bifidobacterium Melhora no perfil lipídico
longum
BL04 (DSM 23233)
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
plantarum Fortalecimento das defesas
naturais do organismo
LP01 (LMG P-21021)
+
Lactobacillus
plantarum LP02
2.5 bilhões UFC
(LMG P-21020) Redução de desconforto +
+ gastrointestinal 2.5 bilhões UFC
+
Lactobacillus Human clinical trial: Pregliasco F, Anselmi G, Fonte L, Giussani F, Schieppati S, 2.5 bilhões UFC
rhamnosus Soletti L. A New Chance of Preventing Winter Diseases by the Administration of +
Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233. 2.5 bilhões UFC
LR04 (DSM 16605) +
+ 5 bilhões UFC
Equlíbrio da microbiota intestinal +
Lactobacillus FOS or GOS
rhamnosus
LR05 (DSM 19739)
+
Redução da incidência,
Bifidobacterium gravidade e duração de infecção
animalis subsp. lactis aguda respiratória (IAR) em
BS01 (LMG P-21384) estações frias
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Bifidobacterium
breve Melhora da resposta imune
BR03 (DSM 16604) 5 bilhões UFC
Human clinical trial: Jäger R. et al. Probiotic supplementation attenuates performance
+ decrements and inflammation following muscle damaging exercise. Under publication
+
5 bilhões UFC
Streptococcus
Aumento da performance em
thermophilus exercícios
FP4 (DSM 18616)
breve
Restauração da barreira
BR03 (DSM 16604) fisiológica intestinal
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
rhamnosus
LR06 (DSM 21981)
+ Microbiota oral saudável
Lactobacillus
pentosus
1.5 bilhões UFC
LPS01 (DSM 21980) +
+ Human clinical trial: Del Piano M. et al. Correlation between specific bacterial groups in 1.5 bilhões UFC
the oral cavity and the severity of halitosis: any possible beneficial role for selected +
Lactobacillus Lactobacilli? J Gastroint Dig Syst, 2014; 4:197 1.5 bilhões UFC
+
plantarum
500 milhões UFC
LP01 (LMG P-21021)
+ Melhora da incidência e
Lactobacillus gravidade do mau hálito
delbrueckii (halitose)
subsp. delbrueckii
LDD01 (DSM 22106)
Lactobacillus
Saúde Vaginal 400 milhões
fermentum UFC/cepas/tabletes
LF15 (DSM 26955) Human clinical trial: Vicariotto F. et al. Effectiveness of the two microorganisms L. +
fermentum LF15 and L. plantarum LP01, formulated in slow release vaginal tablets, in Goma de tara
+ Inibição de Gardnerella Vaginalis women affected by Bacterial Vaginosis: a pilot study. J Clin Gastroenterol. 2014; 48 +
Lactobacillus Suppl:S106-112. FOS
+
plantarum Neutralização de vaginose Arabinogalactan
LP01 (LMG P-21021) bacteriana
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Bifidobacterium
longum DLBL07
(DSM 25669)
+
Bifidobacterium
longum DLBL08
(DSM 25670)
+
Human clinical trial: Drago L. et al. Cultivable and pyrosequenced fecal microflora in
Bifidobacterium centenarians and young subjects. J Clin Gastroenterol. 2012; 46 Suppl:S81-4. In vitro
longum DLBL09 Equlíbrio da microbiota intestinal study: Nicola S. et al. Immunomodulatory properties of Bifidobacterium longum DLBL
strains isolated from centenarians. Publication in progress in a Supplement to the Journal
(DSM 25671) of Clinical Gastroenterology.
+
Bifidobacterium
longum DLBL10
(DSM 25672)
+
Bifidobacterium
longum DLBL11
(DSM 25673)
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Saúde Vaginal
Lactobacillus
1,2) 400 milhões
fermentum Inibição de cepas de candida Human clinical trials: 1)Vicariotto F. et al. Effectiveness of the association of 2 probiotic UFC/cepas/tabletes
LF10 (DSM 19187) strains formulated in a slow release vaginal product, in women affected by vulvovaginal +
candidiasis: a pilot study. J Clin Gastroenterol. 2012; 46 Suppl:S73-80. 2)Murina F. et al. Dióxido de Carbono
+
Tablete efervescente de lenta Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a Slow-release +
Lactobacillus liberação, melhorando a chegada Vaginal Product be Useful for Prevention of Recurrent Vulvovaginal Candidiasis? J Clin FOS
Gastroenterol. 2014; 48 Suppl:S102-105 +
acidophilus LA02 e a atividade do lactobacilo
Arabinogalactan
(DSM 21717)
Neutralização de candidíase
vulvovaginal
Lactobacillus
gasseri
LGS01 (DSM 18299)
+ Saúde Vaginal
Lactobacillus
crispatus
LCR01 (DSM 24619)
+
Lactobacillus
Equilíbrio saudável da microbiota
fermentum vaginal
In vitro data on individual strains
Lactobacillus
paracasei Equilíbrio da microbiota intestinal
LPC09 (DSM 24243)
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
acidophilus Neutralização de candidíase
LA02 (DSM 21717) vulvovaginal
Lactobacillus
rhamnosus Neutralização de vaginose
LR06 (DSM 21981) bacteriana
Combinações
DOSAGEM DIÁRIA
ID FUNCIONALIDADE COMPROVAÇÃO CIENTÍFICA
ESTUDADA
Lactobacillus
rhamnosus
LR06 (DSM 21981)
1) 3 bilhões UFC
+ Restauração da barreira +
fisiológica intestinal
Lactobacillus 3 bilhões UFC
+
pentosus 3 bilhões UFC
Human clinical trials: 1) Del Piano M. et al. The innovative potential of Lactobacillus
LPS01 (DSM 21980) +
rhamnosus LR06, Lactobacillus pentosus LPS01, Lactobacillus plantarum LP01, and
1 bilhão UFC
+ Lactobacillus delbrueckii subsp. delbrueckii LDD01 to restore the “gastric barrier effect” in
+
patients chronically treated with PPI: a pilot study. J Clin Gastroenterol. 2012; 46
FOS
Lactobacillus Suppl:S18-26. 2) Del Piano M. et al. Correlation between chronic treatment with Proton
2) 3 bilhões UFC
Pump Inhibitors (PPIs) and bacterial overgrowth in the stomach: any possible beneficial
plantarum role for selected Lactobacilli? J Clin Gastroenterol. 2014; 48 Suppl:S40-46.
+
Atenuação dos efeitos colaterais 3 bilhões UFC
LP01 (LMG P-21021) +
induzidos pela "barreira
+ gástrica", causados por uso 3 bilhões UFC
+
Lactobacillus prolongado de drogas ácido-
1 bilhão UFC
delbrueckii supressoras, tais como
inibidores da bomba de prótons
subsp. delbrueckii
LDD01 (DSM 22106)
Lactobacillus
salivarius
subsp. salivarius
In vitro study: Drago L. et al. Immunomodulatory effects of Lactobacillus salivarius LS01
LS01 (DSM 22775) Efeito imunomodulador and Bifidobacterium breve BR03, alone and in combination, on peripheral blood
relacionado a asma mononuclear cells of allergic asthmatics. Allergy Asthma Immunol Res. 2015 July;
+
7(4):409-413
Bifidobacterium
breve
BR03 (DSM 16604)
Referências
• OUR PROBIOTIC STRAINS, PROBIOTICAL. Acesso em: 12/07/2017.
Disponível em: <http://bart.pl/wp-content/uploads/2016/02/Ceppi-
Probiotical-2014-1.pdf>.
• LONGO, S.A.; MOORE, R.C.; CANZONERI, B.J.; ROBICHAUX, A.
Gastrointestinal Conditions during Pregnancy. Clin Colon Rectal Surg. v.
23, n. 2, p. 80-89, 2010.